陽光諾和(688621.SH):擬16.11億元購買朗研生命100%股權
格隆匯4月11日丨陽光諾和(688621.SH)公佈,公司擬向利虔、朗頤投資等38名朗研生命全體股東以發行股份及支付現金方式購買其所持有的標的公司100%股權;同時,公司擬向不超過35名特定對象發行股份募集配套資金。北京朗研生命科技控股有限公司100%股權的交易作價為16.11億元。標的公司堅持以彌補未被滿足的臨牀需求為導向,專注於高端化學藥及原料藥的研發、生產和銷售,並對外提供藥品生產服務。
公司通過本次交易,主營業務將進一步向CDMO業務領域延伸,構建“CRO+CDMO”一體化服務平台,為客户提供“臨牀前研究+臨牀研究+定製化生產”綜合服務,構建上市公司“研發+生產”一體化服務體系,提升上市公司在所處行業的競爭實力,完善上市公司的戰略佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.